Breaking News Instant updates and real-time market news.

ANGO

AngioDynamics

$16.30

-0.52 (-3.09%)

, HRC

Hill-Rom

$53.34

-0.62 (-1.15%)

04:55
12/01/16
12/01
04:55
12/01/16
04:55

Evercore ISI to hold a forum

MedTools & Outsourcing Investor Forum is being held in Boston on November 30-December 1.

ANGO

AngioDynamics

$16.30

-0.52 (-3.09%)

HRC

Hill-Rom

$53.34

-0.62 (-1.15%)

PACB

Pacific Biosciences

$7.61

-0.09 (-1.17%)

PRXL

PAREXEL

$59.00

0.05 (0.08%)

QTNT

Quotient

$4.30

-0.13 (-2.93%)

SRTS

Sensus Healthcare

$6.00

0.2475 (4.30%)

VAR

Varian Medical

$89.83

-1.53 (-1.67%)

VCYT

Veracyte

$7.63

-0.2 (-2.55%)

KTWO

K2M Group

$18.80

0.11 (0.59%)

INGN

Inogen

$64.43

-0.72 (-1.11%)

  • 01

    Dec

  • 01

    Dec

  • 06

    Dec

  • 07

    Dec

  • 07

    Dec

  • 12

    Dec

  • 09

    Feb

ANGO AngioDynamics
$16.30

-0.52 (-3.09%)

11/04/16
11/04/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Yum China (YUMC) initiated with a Market Perform at Bernstein. 2. PTC (PTC) initiated with a Buy at Goldman. 3. ALLETE (ALE) initiated with a Neutral at Macquarie. 4. Array BioPharma (ARRY) initiated with an Outperform at Cowen. 5. AngioDynamics (ANGO) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/08/16
PIPR
04/08/16
INITIATION
Target $12
PIPR
Neutral
AngioDynamics assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Brooks West assumed coverage of AngioDynamics with a Neutral rating and $12 price target. The company's investment is clouded in the near-term given the recent management changes, West tells investors in a research note following AngioDynamics' Q3 results.
04/05/16
ADAM
04/05/16
DOWNGRADE
ADAM
Hold
AngioDynamics downgraded to Hold from Buy at Canaccord
11/03/16
CANT
11/03/16
INITIATION
Target $19
CANT
Buy
AngioDynamics initiated with a Buy at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier started AngioDynamics with a Buy rating and $19 price target.
HRC Hill-Rom
$53.34

-0.62 (-1.15%)

06/16/16
MSCO
06/16/16
UPGRADE
MSCO
Overweight
Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
07/19/16
MSCO
07/19/16
NO CHANGE
MSCO
Morgan Stanley's highest conviction stocks into earnings
Morgan Stanley highlighed 14 stocks with the highest analyst conviction into earnings. The firm's analyst view earnings as a positive catalyst for BankUnited (BKU), Concho Resources (CXO), Hill-Rom (HRC), lululemon (LULU), Microsoft (MSFT), NXP Semiconductors (NXPI), Pfizer (PFE), Priceline (PCLN), and Sherwin-Williams (SHW) and sees earnings as a negative catslyst for Gilead (GILD), Nordstrom (JWN), Rackspace (RAX), Relypsa (RLYP), and United Natural Foods (UNFI).
06/16/16
MSCO
06/16/16
UPGRADE
Target $62
MSCO
Overweight
Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley upgraded Hill-Rom to Overweight from Equal Weight. Analyst David Lewis said share weakness following Q2 results has created an a compelling entry point and the Street does not appreciate the extent Hill-Rom has created a sustainable sales base and margin expansion potential. The firm's checks indicate the U.S. capital business remains robust and margins are up with a better balance of organic improvement on top of mix/synergies continuing.
09/23/16
RHCO
09/23/16
NO CHANGE
RHCO
Compass Diversified deal should remove 'key overhang,' says SunTrust
After Compass agreed to sell its Tridein Medical unit to Hill-Rom (HRC), SunTrust analyst Douglas Mewhirter says that Tridein is a "small but troublesome portfolio company." He thinks the deal removes a "key overhang" on Compass, and he reiterates a Buy rating on the stock.
PACB Pacific Biosciences
$7.61

-0.09 (-1.17%)

08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.
08/18/16
CANT
08/18/16
NO CHANGE
Target $165
CANT
Speculative Buy
Thermo Fisher unlikely to acquire Illumina, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier believes it is unlikely that Thermo Fisher (TMO) will attempt to acquire Illumina (ILMN). Even if Thermo were to attempt a deal, the merger would be unlikely to close, Brokmeier tells investors in an intraday research note. If Illumina is a willing seller, however, Roche (RHHBY) may reconsider a bid, the analyst contends. He recommends investors stay on the sidelines with respect to Illumina shares. Brokmeier has a Hold rating on the name with a $165 price target. The analyst continues to believe Roche is the most likely acquirer of Pacific Biosciences (PACB).
04/18/16
PIPR
04/18/16
NO CHANGE
Target $11
PIPR
Neutral
Pacific Biosciences estimates lowered on Sequel checks at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his Q1 estimates for Pacific Biosciences after his initial round of Sequel channel checks found six placements during the quarter compared to the 17 he modeled. Assuming Roche placed five systems, the Q1 total would come to 11, Quirk tells investors in a research note. The analyst keeps a Neutral rating on the shares with an $11 price target.
04/22/16
CANT
04/22/16
NO CHANGE
CANT
Pacific Biosciences should be bought after strong Q1 results, says Cantor
Cantor recommends that investors buy the shares of Pacific Biosciences after the company reported stronger than expected Q1 results. The firm thinks that the company's increased guidance may be conservative, and it believes that the company could have at least 30 bookings in Q2. Cantor keeps an $18 price target and Buy rating on the shares.
PRXL PAREXEL
$59.00

0.05 (0.08%)

11/11/16
RHCO
11/11/16
DOWNGRADE
RHCO
Hold
PAREXEL downgraded on execution risk at SunTrust
As noted earlier, SunTrust downgraded PAEXEL to Hold from Buy. Analyst Sandy Draper downgraded the stock after the company announced that it was delaying the issuance of its 10Q due to inappropriate revenue recognition issues. The analyst says that this news, along with the delay of its previous 10Q due to financial irregularities, the unexpected departure of its CFO and its cancellation of strategic partnerships earlier this year, lead him to question the company's execution and controls. Target $60.
11/17/16
FANA
11/17/16
DOWNGRADE
FANA
Equal-Weight
PAREXEL downgraded to Equal-Weight from Overweight at First Analysis
11/17/16
FANA
11/17/16
DOWNGRADE
Target $62
FANA
Equal-Weight
PAREXEL downgraded to Equal-Weight from Overweight at First Analysis
First Analysis analyst Steven Schwartz downgraded PAREXEL to Equal-Weight citing uncertainty for revenue and earnings growth. The company is seeing a higher level of project cancellations and lower backlog conversion, Schwartz tells investors in a research note. He lowered his price target for the shares to $62 from $85.
11/23/16
WELS
11/23/16
DOWNGRADE
WELS
Market Perform
PAREXEL downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Tim Evans downgraded PAREXEL to Market Perform after reviewing the company's quarterly filing. Unresolved material weakness in controls, high cancellations "defying clear explanation" and a Q1 restatement create risk that another guidance cut is likely, Evans tells investors in a research note. He cut his price target range for the shares to $60-$65 from $70-$75.
QTNT Quotient
$4.30

-0.13 (-2.93%)

SRTS Sensus Healthcare
$6.00

0.2475 (4.30%)

VAR Varian Medical
$89.83

-1.53 (-1.67%)

10/20/16
SBSH
10/20/16
NO CHANGE
SBSH
General Electric takeover of Varian Medical unlikely, says Citi
Citigroup said General Electric (GE) exited the radiation oncology space in the 1990's and since then has had virtually no interest in getting into the treatment side of healthcare versus diagnostics. Further, the firm's analyst said Varian (VAR) is in the midst of spinning off their imaging business, and in theory, would make Varian a much more attractive target for General Electric. However, Citi said a takeover of Varian before the spin closing in December would make no sense by General Electric and reduces the firm's belief in today's speculation.
01/12/16
BRRR
01/12/16
INITIATION
Target $91
BRRR
Outperform
Varian Medical assumed with an Outperform at Barrington
Barrington analyst Michael Petusky assumed coverage of Varian Medical with an Outperform rating and $91 price target.
07/08/16
BARD
07/08/16
NO CHANGE
Target $84
BARD
Neutral
No change in PFS proposed rates a positive for Varian Medical, says Baird
Baird analyst Jeff Johnson noted that CMS released CY 2017 proposed payment rates under the Physician Fee Schedule and said the flat proposed rate changes for a typical radiation freestanding center next year is a positive for Varian Medical. While the flat proposed rate is in-line with management guidance, will still likely come as a relief for investors, said Johnson, who keeps a Neutral rating and $84 price target on Varian shares.
04/28/16
BMUR
04/28/16
NO CHANGE
Target $87
BMUR
Buy
Varian Medical price target raised to $87 from $82 at Brean Capital
Brean Capital raised its price target on Varian Medical to $87 from $82 following mixed Q2 results. The firm cited its lowered guidance, which they now see as achievable. Brean Capital reiterated its Buy rating on Varian Medical shares.
VCYT Veracyte
$7.63

-0.2 (-2.55%)

11/29/16
11/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying he sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders. 2. Comerica (CMA) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Tractor Supply (TSCO) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying he expects the company to benefit from colder weather and the improving US economy and said product assortments and promotions have also been adjusted to the new economics of the energy patch and its impact on this company's customers. 4. Del Frisco's (DFRG) upgraded to Outperform from Neutral at Credit Suisse with analyst Jason West saying it is a key beneficiary of improved high-end consumer and corporate spending. 5. Veracyte upgraded to Buy from Neutral at Janney Capital with analyst Paul Knight saying the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/16
JANY
11/29/16
UPGRADE
JANY
Buy
Veracyte upgraded at Janney Capital
As noted earlier, Janney Capital upgraded Veracyte to Buy from Neutral. Analyst Paul Knight says that the company's "disciplined test development, commercialization, and reimbursement processes" insulate it from a number of problems plaguing the pharma sector. He thinks that recent regulatory changes have "dramatically reduced" the company's pricing risk. Target to $16 from $8.
11/29/16
JANY
11/29/16
UPGRADE
JANY
Buy
Veracyte upgraded to Buy from Neutral at Janney Capital
11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees tax holiday as potential catalyst for Medical Diagnostics space
A repatriation tax holiday represents a potential catalyst for the Medical Diagnostics space, Piper Jaffray analyst William Quirk tells investors in a research note. Quirk notes that Becton Dickinson (BDX), Illumina (ILMN) and PerkinElmer (PKI) disclose cash held overseas and that all have highlighted share repurchases and acquisitions as priorities. He believes a repatriation event could be a catalyst for small lab deals. Acquisition targets include CareDx (CDNA), Genomic Health (GHDX), Oxford Immunotec (OXFD), Trovagene (TROV) and Veracyte (VCYT), Quirk tells investors.
KTWO K2M Group
$18.80

0.11 (0.59%)

10/10/16
RBCM
10/10/16
INITIATION
RBCM
Outperform
K2M Group initiated with an Outperform at RBC Capital
RBC Capital analyst Glenn Novarro started K2M with an Outperform rating and a target of $23.
08/25/16
PIPR
08/25/16
NO CHANGE
PIPR
K2M Group has positive read through from distributor results, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says that K2M's Australian distributor, LifeHealthcare, reported higher than expected fiscal 2016 revenue. The analyst adds that the distributor was a major factor behind the lowering of K2M's guidance earlier this year. He thinks that K2M's valuation is attractive and keeps an Overweight rating on the shares.
11/16/16
PIPR
11/16/16
NO CHANGE
PIPR
Piper says NuVasive, Novadaq pullbacks overdone
Piper Jaffray analyst Matt O'Brien views the post-earnings pullbacks in shares of NuVasive (NUVA) and Novadaq (NVDQ) as overdone. The analyst believes the stocks are disconnected from the intrinsic value of the companies. O'Brien also sees further room to run for shares of K2M Group (KTWO) and ZELTIQ (ZLTQ).
11/11/16
PIPR
11/11/16
NO CHANGE
PIPR
Overweight
K2M should be bought on any stock sale selloff, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends using any weakness in K2M Group from Welsh Carson's 4.5M share sale as a buying opportunity. The analyst believes the sale does not speak to any fundamental weakness in the story. He keeps an Overweight rating on K2M Group.
INGN Inogen
$64.43

-0.72 (-1.11%)

08/05/16
STFL
08/05/16
DOWNGRADE
STFL
Hold
Inogen downgraded to Hold from Buy at Stifel
09/09/16
JPMS
09/09/16
NO CHANGE
Target $70
JPMS
Overweight
Inogen price target raised to $70 from $62 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Inogen to $70 after hosting investor meetings with the company's CEO and COO. The analyst calls the meetings "bullish" and notes that management sees near-to-midterm sales growth in the 20%-plus range with faster earnings growth. Marcus reiterates an Overweight rating on the shares.
08/05/16
NEED
08/05/16
NO CHANGE
Target $64
NEED
Strong Buy
Inogen price target raised to $64 from $58 at Needham
Needham analyst Mike Matson raised his price target for Inogen to $64 from $58 after the company reported better than expected second quarter revenue, EBITDA, and EPS, and raised its 2016 guidance. The analyst reiterates a Strong Buy on the shares, saying "the positives outweigh the negatives." Matson views any weakness in Inogen's shares as a buying opportunity ahead of a "major" G4-driven product cycle.
08/05/16
STFL
08/05/16
DOWNGRADE
STFL
Hold
Inogen downgraded on valuation at Stifel
As noted earlier, Stifel downgraded Inogen to Hold from Buy. Analyst Thomas Carroll downgraded the stock based o nvaluation.

TODAY'S FREE FLY STORIES

DE

Deere

$101.50

-1.2 (-1.17%)

13:12
12/04/16
12/04
13:12
12/04/16
13:12
Periodicals
Deere could keep climbing, Barron's says »

Deere stock recently…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCP

J.C. Penney

$9.81

0.28 (2.94%)

, GME

GameStop

$24.27

-0.37 (-1.50%)

12:57
12/04/16
12/04
12:57
12/04/16
12:57
Periodicals
Corporate tax cut can't save all retailers, Barron's says »

Though President-elect…

JCP

J.C. Penney

$9.81

0.28 (2.94%)

GME

GameStop

$24.27

-0.37 (-1.50%)

AEO

American Eagle

$16.17

-0.57 (-3.41%)

TJX

TJX

$77.10

-0.57 (-0.73%)

FL

Foot Locker

$74.23

0.55 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

ELY

Callaway Golf

$11.68

-0.3 (-2.50%)

12:40
12/04/16
12/04
12:40
12/04/16
12:40
Periodicals
Callaway Golf investors should take profits, Barron's says »

It "looks like a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVC

Entravision

12:36
12/04/16
12/04
12:36
12/04/16
12:36
Periodicals
Entravision shares could reach $9, Barron's says »

Hispanic-focused…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

GOOG

Alphabet

$750.50

2.58 (0.34%)

, GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

12:26
12/04/16
12/04
12:26
12/04/16
12:26
Periodicals
Barron's picks top ten stocks for 2017 »

Selecting its ten…

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

AAPL

Apple

$109.90

0.41 (0.37%)

C

Citi

$56.02

-1.25 (-2.18%)

DAL

Delta Air Lines

$48.31

0.54 (1.13%)

DTEGY

Deutsche Telekom

$15.65

0.14 (0.90%)

MRK

Merck

$61.13

0.37 (0.61%)

NVS

Novartis

$68.17

0.42 (0.62%)

TOL

Toll Brothers

$29.32

0.18 (0.62%)

UL

Unilever; also tag UN

$39.67

0.5 (1.28%)

UN

Unilever; also tag UL

$39.47

0.35 (0.89%)

DIS

Disney

$98.50

-0.44 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 12

    Dec

  • 15

    Jan

  • 26

    Jan

  • 08

    Mar

  • 13

    Mar

TWTR

Twitter

$17.93

-0.1 (-0.55%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Periodicals
Early Twitter investor Sacca would 'love' to see the company sold, CNBC reports »

One of the earliest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

10:55
12/04/16
12/04
10:55
12/04/16
10:55
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

CELG

Celgene

$117.63

-1.24 (-1.04%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Celgene to hold an analyst and investor event »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

04:55
12/04/16
12/04
04:55
12/04/16
04:55
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.